Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1436-1441

  Gori, S ^a   Montemurro, F ^b   Spazzapan, S ^c   Metro, G ^a   Foglietta, J ^a   Bisagni, G ^d   Ferzi, A ^e   Silva, R R ^f   Gamucci, T ^g   Clavarezza, M ^h   Stocchi, L ^a   Fabi, A ⁱ   Cognetti, F ⁱ   Torrisi, E ^c   Crivellari, D ^c  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e Ospedale Civile di Legnano   (Italy)

^f Ospedale E Profili   (Italy)

^g Department of Medical Oncology   (Italy)

^h SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HER2; Metastatic breast cancer; Trastuzumab after lapatinib

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER REGRESSION; CARDIOTOXICITY; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; SIDE EFFECT; VISCERAL METASTASIS;

EID: 84861735490     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr474     Document Type: Article

References (25)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
3. Dahabreh IJ, Linardou H, Siannis F et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 3: 620-630.
4. Gianni L, Dafni U, Gelber RD et al. for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-244.
5. von Minckwitzdu A, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009; 27: 1999-2006.
6. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
7. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
8. Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119.
9. Valabrega G, Montemurro F, Sarotto I et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005; 24: 3002-3010.
10. Lu Y, Li X, Liang K et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007; 67: 8240-8247.
11. Scaltriti M, Verma C, Guzman M et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumabdependent cell cytotoxicity. Oncogene 2009; 28: 803-814.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003; 4: 120-125.
14. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
15. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5: 52-58.
16. Stemmler HJ, Kahlert S, Siekiera W et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005; 28: 582-586.
17. Cancello G, Montagna E, D'Agostino D et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008; 10: R60.
18. Extra J-M, Antoine EC, Vincent-Salomon A et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010; 15: 779-809.
19. Montemurro F, Donadio M, Clavarezza M et al. Out come of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
20. Spazzapan S, Crivellari D, Tumolo S et al. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a monoinstitutional experience. J Clin Oncol 2010; 28 (Suppl): 15S Abstr 1082.
21. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28: 1301-1307.
22. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
23. Burris HA III, Rugo HS, Vukelija SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2010; 28: 398-405.
24. Dalenc F, Campone M, Hupperets P et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial. J Clin Oncol 2010; 28 (Suppl): 15S. Abstr 1013.
25. Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2-overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-5417.